Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

The deregulation of translation markedly contributes to the malignant phenotype in cancers, and the assembly of the translation initiating complex eIF4F is the limiting step of this process. The mammalian Target of Rapamycin Complex 1 (mTORC1) is thought to positively regulate eIF4F assembly and subsequent oncogenic protein synthesis through 4E-BP1 phosphorylation. We showed here that the translation inhibitor 4EGI-1 decreased the clonogenic growth of leukemic progenitors and induced apoptosis of blast cells, with limited toxicity against normal hematopoiesis, which emphasize the importance of translation deregulation in acute myeloid leukemia (AML) biology. However, the mTORC1 inhibitor RAD001 (a rapamycin derivate) did not induce AML blast cell apoptosis. We herein demonstrated that mTORC1 disruption using raptor siRNA or RAD001 failed to inhibit 4E-BP1 phosphorylation in AML. Moreover, RAD001 failed to inhibit eIF4F assembly, to decrease the proportion of polysome-bound c-Myc mRNA, and to reduce the translation-dependent accumulation of oncogenic proteins. We identified the Pim-2 serine/threonine kinase as mainly responsible for 4E-BP1 phosphorylation on the S(65) residue and subsequent translation control in AML. Our results strongly implicate an mTORC1-independent deregulation of oncogenic proteins synthesis in human myeloid leukemogenesis. Direct inhibition of the translation initiating complex thus represents an attractive option for the development of new therapies in AML.

[1]  Zhang Jin-lin.  Progress in the treatment of acute myeloid leukemia , 2010 .

[2]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[3]  Sang Gyun Kim,et al.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.

[4]  K. Shokat,et al.  PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML , 2008, Leukemia.

[5]  C. Récher,et al.  A critical role for Lyn in acute myeloid leukemia. , 2008, Blood.

[6]  P. Rothman,et al.  Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. , 2008, Blood.

[7]  E. Cohen.  mTOR: the mammalian target of replication. , 2008, Journal of Clinical Oncology.

[8]  E. Campo,et al.  Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2001:62-86. PMID: 11722979 , 2008 .

[9]  R. Abraham,et al.  Mammalian target of rapamycin as a therapeutic target in oncology. , 2008, Expert opinion on therapeutic targets.

[10]  S. Koschmieder,et al.  Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation , 2008, Leukemia.

[11]  J. Tamburini,et al.  Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.

[12]  H. Kantarjian,et al.  Progress in the treatment of acute myeloid leukemia , 2007, Cancer.

[13]  Tao Wang,et al.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.

[14]  F. Khuri,et al.  Inhibition of Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase-Dependent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphorylation , 2007, Molecular and Cellular Biology.

[15]  Philippe Broët,et al.  Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. , 2007, Blood.

[16]  S. Knapp,et al.  Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.

[17]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[18]  R. Roth,et al.  PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding* , 2007, Journal of Biological Chemistry.

[19]  D. Sabatini,et al.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. , 2007, Blood.

[20]  C. Proud.  Signalling to translation: how signal transduction pathways control the protein synthetic machinery. , 2007, The Biochemical journal.

[21]  A. Degterev,et al.  Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G , 2007, Cell.

[22]  B. Werneburg,et al.  Pim kinase substrate identification and specificity. , 2006, Journal of biochemistry.

[23]  N. Sonenberg,et al.  mTOR, translation initiation and cancer , 2006, Oncogene.

[24]  Shile Huang,et al.  Predicted mechanisms of resistance to mTOR inhibitors , 2006, British Journal of Cancer.

[25]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[26]  M. Nawijn,et al.  Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. , 2006, Cancer research.

[27]  M. Carroll,et al.  mTOR regulates cell survival after etoposide treatment in primary AML cells. , 2005, Blood.

[28]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[29]  P. Hammerman,et al.  Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. , 2005, Blood.

[30]  M. Fleming,et al.  Pim-1 Ligand-bound Structures Reveal the Mechanism of Serine/Threonine Kinase Inhibition by LY294002* , 2005, Journal of Biological Chemistry.

[31]  G. Laurent,et al.  Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.

[32]  E. Solary,et al.  Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.

[33]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[34]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.

[35]  A. Kraft,et al.  The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death* , 2003, Journal of Biological Chemistry.

[36]  C. Proud,et al.  Target of Rapamycin (TOR)-signaling and RAIP Motifs Play Distinct Roles in the Mammalian TOR-dependent Phosphorylation of Initiation Factor 4E-binding Protein 1* , 2003, Journal of Biological Chemistry.

[37]  L. Chodosh,et al.  The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. , 2003, Genes & development.

[38]  Chunaram Choudhary,et al.  Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. , 2003, Blood.

[39]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[40]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[41]  J. Dupont,et al.  In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes : evidence for Fas-dependent apoptosis , 2002 .

[42]  Shile Huang,et al.  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. , 2002, Current opinion in investigational drugs.

[43]  S K Burley,et al.  Hierarchical phosphorylation of the translation inhibitor 4E-BP1. , 2001, Genes & development.

[44]  J. Warwicker,et al.  A Quantitative Molecular Model for Modulation of Mammalian Translation by the eIF4E-binding Protein 1* , 2001, The Journal of Biological Chemistry.

[45]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[46]  J. Radich,et al.  Acute myeloid leukemia. , 2001, Hematology. American Society of Hematology. Education Program.

[47]  A. Gingras,et al.  eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. , 1999, Annual review of biochemistry.

[48]  A. Berns,et al.  Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc , 1997, Oncogene.

[49]  D. Morris,et al.  Initiation codons within 5'-leaders of mRNAs as regulators of translation. , 1994, Trends in biochemical sciences.

[50]  A. Berns,et al.  Evidence for the involvement of pim‐2, a new common proviral insertion site, in progression of lymphomas. , 1989, The EMBO journal.

[51]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[52]  N. Sonenberg,et al.  The involvement of mRNA secondary structure in protein synthesis. , 1987, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[53]  A. Berns,et al.  Proviral activation of the putative oncogene Pim‐1 in MuLV induced T‐cell lymphomas. , 1985, The EMBO journal.